Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines
Regeneron Pharmaceuticals (NASDAQ: REGN) has announced a major expansion of its manufacturing capacity through a new agreement with FUJIFILM Diosynth Biotechnologies. The 10-year partnership, valued at over $3 billion, will nearly double Regeneron's U.S. large-scale manufacturing capacity using Fujifilm's Holly Springs, North Carolina facility.
The company is also investing heavily in its New York operations, with a $3.6 billion expansion of its Tarrytown campus that will create 1,000 full-time, high-skill jobs. Additional developments include a new fill/finish manufacturing facility in Rensselaer and acquisition of a 1+ million-square-foot property in Saratoga Springs for production support and potential manufacturing.
Over the past five years, Regeneron has added more than 7,000 jobs, primarily in R&D and manufacturing within the United States. The company's total planned investments in New York and North Carolina infrastructure and manufacturing are expected to exceed $7 billion.
Regeneron Pharmaceuticals (NASDAQ: REGN) ha annunciato una significativa espansione della sua capacità produttiva attraverso un nuovo accordo con FUJIFILM Diosynth Biotechnologies. La partnership decennale, del valore di oltre 3 miliardi di dollari, quasi raddoppierà la capacità produttiva su larga scala di Regeneron negli Stati Uniti, sfruttando la struttura di Fujifilm a Holly Springs, nella Carolina del Nord.
L'azienda sta inoltre investendo massicciamente nelle sue operazioni di New York, con un'espansione da 3,6 miliardi di dollari del campus di Tarrytown che creerà 1.000 posti di lavoro a tempo pieno e altamente qualificati. Altri sviluppi includono una nuova struttura per il riempimento e la finitura a Rensselaer e l'acquisizione di una proprietà di oltre un milione di piedi quadrati a Saratoga Springs per supporto alla produzione e potenziali attività manifatturiere.
Negli ultimi cinque anni, Regeneron ha creato più di 7.000 posti di lavoro, principalmente nel settore della ricerca e sviluppo e della produzione negli Stati Uniti. Gli investimenti totali pianificati dall'azienda nelle infrastrutture e nella produzione di New York e Carolina del Nord supereranno i 7 miliardi di dollari.
Regeneron Pharmaceuticals (NASDAQ: REGN) ha anunciado una importante expansión de su capacidad de fabricación mediante un nuevo acuerdo con FUJIFILM Diosynth Biotechnologies. La asociación de 10 años, valorada en más de 3 mil millones de dólares, casi duplicará la capacidad de fabricación a gran escala de Regeneron en EE. UU., utilizando la planta de Fujifilm en Holly Springs, Carolina del Norte.
La compañía también está realizando una fuerte inversión en sus operaciones de Nueva York, con una expansión de 3.6 mil millones de dólares en su campus de Tarrytown que creará 1,000 empleos a tiempo completo y altamente especializados. Otros desarrollos incluyen una nueva planta de llenado y acabado en Rensselaer y la adquisición de una propiedad de más de un millón de pies cuadrados en Saratoga Springs para apoyo a la producción y posible fabricación.
En los últimos cinco años, Regeneron ha añadido más de 7,000 empleos, principalmente en I+D y manufactura dentro de Estados Unidos. Se espera que las inversiones totales planificadas por la compañía en infraestructura y fabricación en Nueva York y Carolina del Norte superen los 7 mil millones de dólares.
Regeneron Pharmaceuticals (NASDAQ: REGN)는 FUJIFILM Diosynth Biotechnologies와의 새로운 계약을 통해 제조 능력을 크게 확장한다고 발표했습니다. 10년간의 파트너십으로, 30억 달러 이상의 가치가 있으며, 노스캐롤라이나주 홀리 스프링스에 위치한 후지필름 시설을 활용하여 Regeneron의 미국 내 대규모 제조 능력을 거의 두 배로 늘릴 예정입니다.
이 회사는 또한 뉴욕 사업장에 대규모 투자를 진행 중이며, 테리타운 캠퍼스의 36억 달러 규모 확장을 통해 1,000개의 고숙련 정규직 일자리를 창출할 계획입니다. 추가 개발 사항으로는 렌셀러에 새로운 충진 및 마감 제조 시설 설립과 사라토가 스프링스에 100만 평방피트가 넘는 부동산 인수를 통한 생산 지원 및 잠재적 제조 시설 확보가 포함됩니다.
지난 5년간 Regeneron은 주로 미국 내 연구개발 및 제조 부문에서 7,000개 이상의 일자리를 추가했습니다. 뉴욕과 노스캐롤라이나의 인프라 및 제조 분야에 대한 회사의 총 계획 투자액은 70억 달러를 초과할 것으로 예상됩니다.
Regeneron Pharmaceuticals (NASDAQ : REGN) a annoncé une importante expansion de sa capacité de production grâce à un nouvel accord avec FUJIFILM Diosynth Biotechnologies. Ce partenariat de dix ans, d'une valeur de plus de 3 milliards de dollars, permettra de presque doubler la capacité de production à grande échelle de Regeneron aux États-Unis, en utilisant l'installation de Fujifilm à Holly Springs, en Caroline du Nord.
L'entreprise investit également massivement dans ses opérations à New York, avec une extension de 3,6 milliards de dollars de son campus de Tarrytown, qui créera 1 000 emplois à temps plein hautement qualifiés. Parmi les autres développements, on compte une nouvelle installation de remplissage/finition à Rensselaer et l'acquisition d'un site de plus d'un million de pieds carrés à Saratoga Springs pour le soutien à la production et une éventuelle fabrication.
Au cours des cinq dernières années, Regeneron a créé plus de 7 000 emplois, principalement dans la recherche et développement ainsi que la production aux États-Unis. Les investissements totaux prévus par l'entreprise dans les infrastructures et la production à New York et en Caroline du Nord devraient dépasser 7 milliards de dollars.
Regeneron Pharmaceuticals (NASDAQ: REGN) hat eine bedeutende Erweiterung seiner Produktionskapazitäten durch eine neue Vereinbarung mit FUJIFILM Diosynth Biotechnologies angekündigt. Die zehnjährige Partnerschaft im Wert von über 3 Milliarden US-Dollar wird Regenerons großtechnische Produktionskapazität in den USA nahezu verdoppeln, indem die Einrichtung von Fujifilm in Holly Springs, North Carolina, genutzt wird.
Das Unternehmen investiert außerdem stark in seine Aktivitäten in New York, mit einer 3,6-Milliarden-Dollar-Erweiterung des Campus in Tarrytown, die 1.000 hochqualifizierte Vollzeitstellen schaffen wird. Weitere Entwicklungen umfassen eine neue Abfüll- und Endbearbeitungsanlage in Rensselaer sowie den Erwerb eines über eine Million Quadratfuß großen Grundstücks in Saratoga Springs zur Produktionsunterstützung und möglichen Fertigung.
In den letzten fünf Jahren hat Regeneron mehr als 7.000 Arbeitsplätze geschaffen, hauptsächlich in Forschung und Entwicklung sowie der Produktion in den USA. Die geplanten Gesamtinvestitionen des Unternehmens in Infrastruktur und Produktion in New York und North Carolina werden voraussichtlich 7 Milliarden US-Dollar übersteigen.
- Major manufacturing expansion will double U.S. production capacity
- $3 billion strategic partnership with Fujifilm for 10 years
- $3.6 billion investment in Tarrytown campus creating 1,000 high-skill jobs
- Significant expansion with new facilities in Rensselaer and Saratoga Springs
- Added 7,000 high-paying jobs in past five years
- Large capital expenditure requirements exceeding $7 billion
- Long-term financial commitment with 10-year Fujifilm contract
Insights
Regeneron's $7B manufacturing expansion signals strong growth expectations and removes potential capacity constraints for its biologic medicines portfolio.
This strategic manufacturing expansion represents a significant scaling of Regeneron's production capabilities with profound implications for the company's growth trajectory. By partnering with FUJIFILM Diosynth Biotechnologies, Regeneron will nearly double its U.S. large-scale manufacturing capacity, addressing what appears to be growing demand for its biologic medicines. The immediate technology transfer with a ten-year term shows thoughtful long-term production planning.
Biologics manufacturing requires highly specialized facilities and expertise due to the inherent complexity of these molecules. This partnership leverages Fujifilm's state-of-the-art facility in Holly Springs, NC, dramatically reducing the time-to-capacity compared to building equivalent infrastructure from scratch. The $3 billion agreement reflects the substantial investment needed for cutting-edge biologics production.
What's particularly impressive is Regeneron's comprehensive approach to manufacturing expansion. Beyond the Fujifilm partnership, they're making substantial investments in their New York operations: a $3.6 billion expansion of the Tarrytown campus, construction of a new fill/finish manufacturing facility in Rensselaer, and acquisition of a 1+ million square foot property in Saratoga Springs. This creates a robust, geographically diversified manufacturing network that enhances supply chain resilience – critical for biologics production.
This level of investment signals strong confidence in sustained demand for both commercial products and pipeline candidates, while creating 1,000 new high-skill jobs through the Tarrytown expansion alone. The manufacturing buildout positions Regeneron to effectively translate its scientific innovations into commercial production at scale.
Regeneron's $7B manufacturing investment demonstrates management's confidence in future growth and addresses potential production constraints.
This $7 billion manufacturing investment indicates exceptionally strong confidence in Regeneron's future growth trajectory. The substantial capital commitment represents approximately 11% of the company's current market capitalization, demonstrating management's conviction in long-term demand for their biologic medicines portfolio.
The strategic decision to nearly double U.S. manufacturing capacity addresses a potential production bottleneck that could otherwise constrain revenue growth as more products receive approval or existing products expand to new indications. By securing a ten-year agreement with Fujifilm worth over $3 billion, Regeneron gains manufacturing scale without the full capital burden and lead time of building entirely new facilities.
Regeneron's diversified investment approach across multiple sites in New York and North Carolina creates operational redundancy while supporting the company's vertically integrated business model. The $3.6 billion expansion of its Tarrytown campus, along with new facilities in Rensselaer and Saratoga Springs, strengthens the company's end-to-end capabilities from research through commercial production.
The addition of 7,000 jobs over five years, with 1,000 more high-skill positions coming from the Tarrytown expansion, reflects sustained organizational growth. This capacity expansion supports Regeneron's continued commitment to U.S.-based operations, with over 80% of workforce and assets domestically located.
From a financial perspective, these investments position Regeneron to capitalize on future commercial opportunities while maintaining control over manufacturing quality and supply chain reliability – crucial factors for maintaining margins in the high-value biologics market.
New manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies in North Carolina will enable additional production of Regeneron’s biologic medicines and support high-paying jobs in the region
Regeneron’s ongoing and planned investments in New York and North Carolina infrastructure and manufacturing expected to total more than
TARRYTOWN, N.Y., April 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a significant expansion of its manufacturing capacity through a new agreement with FUJIFILM Diosynth Biotechnologies (“Fujifilm”) to manufacture and supply bulk drug product of Regeneron’s commercial biologic medicines at their Holly Springs, North Carolina, campus. Regeneron, already one of the largest manufacturers of biologics in the world, will nearly double its U.S. large-scale manufacturing capacity by accessing Fujifilm’s new state-of-the-art biopharmaceutical facility. With technology transfer beginning immediately and a ten-year term, the total investment is estimated to exceed
“Regeneron is an American success story, with over 80 percent of our workforce and assets in the U.S. and all of our FDA-approved medicines invented in our New York laboratories. Our innovative approach has filled our commercial and clinical pipeline with important new medicines and driven a need for even more manufacturing capacity to fulfill the promise of our science,” said Leonard Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer of Regeneron. “We are meeting this need through increased investment in New York and North Carolina. We are proud to advance biotech innovation, which directly improves the health of people around the globe, while generating economic growth and high-paying jobs for America itself.”
This new investment underscores Regeneron’s commitment to deliver innovative medicines to patients. Regeneron continues to invest heavily in its New York State operations, where an approximately
“At Regeneron, we have the privilege of making some of the best and most innovative therapeutics in the industry, and we are acutely aware of our impact on people’s lives as we work to help treat or even cure devastating diseases,” said Daniel Van Plew, Executive Vice President and General Manager, Industrial Operations and Product Supply at Regeneron. “We take our role seriously, and our decision to work with Fujifilm reflects our belief that they will meet our high standards and grow with us. We are excited about this unique relationship, and we are already working to bring capacity online at Fujifilm’s biologics manufacturing facility in Holly Springs, North Carolina.”
“Partnering with Regeneron, a global leader in biotechnology and scientific innovation, is a true honor for us, as we bring together our exceptional teams and shared vision to make transformative medicine accessible to patients,” said Lars Petersen, President and Chief Executive Officer of FUJIFILM Diosynth Biotechnologies. “We are honored that Regeneron has the trust and confidence in our teams’ ability to deliver capacity faster, ensuring continuity of supply for patients in need.”
In the past five years, Regeneron has added more than 7,000 jobs, the majority of which are high-paying R&D and manufacturing jobs based in the United States.
About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases and rare diseases.
Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.
For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.
Forward-Looking Statements and Use of Digital Media
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the ability of Regeneron’s collaborators, licensees, suppliers, or other third parties (as applicable), including Fujifilm Diosynth Biotechnologies North Carolina, Inc. (“Fujifilm”), to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”); the potential for any license, collaboration, or supply agreement, including Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable) as well as the manufacturing and supply agreement with Fujifilm discussed in this press release, to be cancelled or terminated; whether the technology transfer contemplated by the manufacturing and supply agreement with Fujifilm referenced in this press release will be achieved in the expected timeframe or at all; the ability of Regeneron to manage supply chains for multiple products and product candidates; the nature, timing, and possible success and therapeutic applications of Regeneron’s Products and Regeneron’s Product Candidates and research and clinical programs now underway or planned; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and new indications for Regeneron’s Products; uncertainty of the utilization, market acceptance, and commercial success of Regeneron’s Products and Regeneron’s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary) on any of the foregoing; safety issues resulting from the administration of Regeneron’s Products and Regeneron’s Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron’s Products and Regeneron’s Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products and Regeneron’s Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement of Regeneron’s Products from third-party payers, including private payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payers and new policies and procedures adopted by such payers; changes in laws, regulations, and policies affecting the healthcare industry; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s Product Candidates (including biosimilar versions of Regeneron’s Products); the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the impact of public health outbreaks, epidemics, or pandemics on Regeneron's business; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection 2 mg), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2024. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.
Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (https://investor.regeneron.com) and its LinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals).
| Contacts: Media Relations Alexandra Bowie alexandra.bowie@regeneron.com | Investor Relations Ryan Crowe Ryan.crowe@regeneron.com |
FAQ
How much is Regeneron investing in its new manufacturing partnership with Fujifilm?
How many jobs will REGN's Tarrytown campus expansion create?
What is the total value of REGN's planned investments in NY and NC manufacturing?
How many jobs has REGN added in the past five years?
What new facilities is REGN developing in New York State?
